---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-25-000076"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:02:30.484990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zymeworks Q3 2025 revenue $27.6M, net loss narrows to $19.6M; positive ZW191 data

## Summary
- Revenue $27.6M (up from $16.0M YoY) driven by $25.0M J&J milestone; net loss $19.6M vs $29.9M.
- Cash resources $299.4M as of Sep 30, 2025; projected runway into 2H-2027 including anticipated milestones.
- Encouraging Phase 1 data for ZW191 (FRα ADC): 53% objective response rate (64% in gynecological cancers).
- First patient dosed in Phase 1 trial of ZW251 (GPC3-targeting ADC) for hepatocellular carcinoma.
- Completed $22.7M in share repurchases (1.44M shares at avg $15.80) under remaining $30.0M program.

## SEC filing metadata
- accession: 0001937653-25-000076
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/0001937653-25-000076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000076/zyme-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-25-000076
- JSON: https://secwatch.observer/filing/0001937653-25-000076.json
- Plain text: https://secwatch.observer/filing/0001937653-25-000076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.